Glucagon-like Peptide-1 in Type 1 Diabetes

Description

The hypotheses to be tested in this application is: GLP-1 will acutely protect arterial endothelial function and reduce pro-atherothrombotic and pro-coagulant effects of repeated hypoglycemia in T1DM.

Conditions

Type1 Diabetes Mellitus

Talk to us

Study Overview

On this page

Study Details

Study overview

The hypotheses to be tested in this application is: GLP-1 will acutely protect arterial endothelial function and reduce pro-atherothrombotic and pro-coagulant effects of repeated hypoglycemia in T1DM.

Reducing Hypoglycemic, Pro-coagulant and Pro-atherothrombotic Responses and Preventing Hypoglycemia Associated Autonomic Failure in Type 1 DM. the Effects of Glucagon-like Peptide-1

Glucagon-like Peptide-1 in Type 1 Diabetes

Condition
Type1 Diabetes Mellitus
Intervention / Treatment

-

Contacts and Locations

Baltimore

University of Maryland, Baltimore, Maryland, United States, 21201

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * 40 (20 males, 20 females) individuals with type 1 diabetes aged 18-50 yr.
  • * HbA1c \< 11.0%
  • * Body mass index \< 40kg • m-2
  • * No clinically diagnosed diabetic tissue complications (i.e. history of retinopathy, neuropathy, stasis ulcers, etc)
  • * Subjects unable to give voluntary informed consent
  • * Pregnancy
  • * Subjects on anticoagulant drugs, anemic or with known bleeding diatheses
  • * Subjects taking any of the following medications will be excluded: non-selective beta blockers,
  • * sedative-hypnotics, anticonvulsants, antiparkinsonian drugs, antipsychotics, antidepressants,
  • * mood stabilizers, CNS stimulants, opioids, hallucinogens
  • * Subjects unwillingness or inability to comply with approved contraception measures
  • * Subjects with a history of severe uncontrolled hypertension (i.e., blood pressure greater than 160/100), heart disease, cerebrovascular incidents
  • * Clinically significant cardiac abnormalities (e.g. heart failure, arrhythmias, ischemic tachycardia, S-T segment deviations, etc.) from history or from cardiac stress testing in subjects ≥ 40 years old.
  • * Pneumonia
  • * Hepatic failure /jaundice
  • * Abnormal results following screening tests and physical examination that are clinically significant
  • * Acute cerebrovascular/ neurological deficit
  • * Fever greater than 38.0 C
  • * Screening Laboratory Tests Exclusion Criteria
  • * Hematocrit lower than 32
  • * WBC lower than 3 thou/ul or greater than 14 thou/ul
  • * Liver function tests: SGOT and SGPT greater than twice upper limit of normal range (i.e. \> 80 U/L)
  • * TBil \> 2 mg/dl
  • * Creatinine \> 1.6 mg/dl
  • * Alkaline phosphatase \> 150U/L
  • * Hepatic transaminase \> 2x normal

Ages Eligible for Study

18 Years to 50 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Maryland, Baltimore,

Study Record Dates

2026-09